Logo
Homepage
Products
Archer 577
Yellow Laser Photocoagulator with Sub-Threshold Technology
Aglaia 577
Intelligent Navigated Laser System
Mona IV
Adaptive Optics Scanning Laser Ophthalmoscope
Saris
Multi-Modal Ophthalmic Imaging System Designed for Animals
Nuage Vi
Auto Axial length/Refractometer
Roadto® Vision
Soft Contact Lenses
Colored Hydrogel Daily Disposable Contact Lens
Colored Hydrogel Monthly Disposable Contact Lens
Silicone Hydrogel Daily Disposable Contact Lens
Silicone Hydrogel Myopia Control Daily Disposable Contact Lens
News
About
Applications
Contact
中文
Robotrak Technologies Delivers MONA Adaptive Optics Scanning Laser Ophthalmoscope to New York Eye and Ear Infirmary of Mount Sinai
2025-10-01

Robotrak Technologies Adaptive Optics Scanning Laser Ophthalmoscope (AOSLO) has been installed at MONA New York Eye and Ear Infirmary of Mount Sinai in New York City. A major breakthrough for Chinese high-end medical equipment in global top-tier hospitals.


20251001-001.jpg


Founded in 1820, the New York Eye and Ear Infirmary of Mount Sinai (NYEE) holds the distinction of being America's first specialty hospital. As a world-renowned leader, it is dedicated to exceptional patient care, groundbreaking research, and advanced medical education in its core specialties. Its expertise spans ophthalmology, otolaryngology, and plastic and reconstructive surgery, continuing its legacy of innovation and excellence.

20251001-002.jpg


Dr. Richard Rosen commended the significant potential of Adaptive Optics in ophthalmology. He presented Robotrak Technologies with the NYEE 1820-2020 photographic collection, inscribing it to honor founder Jie Zhang for his contributions to ophthalmology. Dr. Rosen further encouraged Jie to continue leading his team in translating innovative technologies into tangible treatments for the benefit of eye patients worldwide.

20251001-003.png

20251001-004.png

During the system installation, Dr. Rosen observed hyalocytes imaged by MONA, cells in the vitreous that are difficult to visualize in vivo. He remarked that this ability to visualize hyalocytes live could lead to breakthroughs in understanding vitreous physiology, disease pathogenesis, and drug development, ultimately enabling improved treatments through early intervention and precise medication. Beyond hyalocytes, MONA's unique capabilities extend to imaging microglial cells, photoreceptors, and retinal vascular blood flow. This aligns perfectly with the goals of Dr. Rosen's laboratory, which is dedicated to applying novel technologies to address clinical challenges.

20251001-005.png

The successful deployment of MONA at NYEE serves as a powerful endorsement of Chinese medical innovation on the global stage.This collaboration between leading Chinese and American ophthalmic institutions is set to create new possibilities in global eye care, translating into innovative approaches for the early diagnosis and management of retinal diseases like Diabetic Retinopathy.